Lacklustre Performance Is Driving ChenGuang Biotech Group Co., Ltd.'s (SZSE:300138) Low P/E
With a price-to-earnings (or "P/E") ratio of 13.6x ChenGuang Biotech Group Co., Ltd. (SZSE:300138) may be sending very bullish signals at the moment, given that almost half of all companies in China h
Chenguang Biotech (300138.SZ) has repurchased a total of 5.05% of its shares at a cost of 307 million yuan
Chenguang Biotech (300138.SZ) announced that as of May 7, 2024, the company has approved a special securities repurchase account...
Chenguang Biology (300138.SZ): The company's red pepper, chili extract, peppercorns extract and other products can be used in the field of prepared dishes
Gelonghui, May 9 | Chenguang Biotech (300138.SZ) said on the investor interactive platform that the company's products such as red chili, chili extract, peppercorns extract, and pepper extract can be used in the field of prepared dishes. Natural plant extracts are more in line with consumers' natural and healthy consumption concept. Production technology is mature and stable, and product costs have market advantages.
Chenguang Biotech (300138.SZ) has repurchased a total of 264.21,000 shares at a cost of 302 million yuan
Chenguang Biotech (300138.SZ) announced that as of April 30, 2024, the company will use centralized bidding transactions...
Chenguang Biotech (300138.SZ) announced first-quarter results, net profit of 385.919 million yuan, a decrease of 71.42%
Chenguang Biotech (300138.SZ) released its report for the first quarter of 2024. The company's revenue was 17.3...
Chenguang Biotech (300138.SZ): A total cost of 258 million yuan to buy back 4.06% of the shares
Gelonghui, April 22, 丨 Chenguang Biotech (300138.SZ) announced that as of April 19, 2024, the company had repurchased 21,648,508 shares of the company's shares through a dedicated securities account, with a transaction amount of RMB 257,655,435.24 (excluding transaction fees). The repurchased shares accounted for 4.06% of the company's total share capital. The highest transaction price of the shares repurchased was 14 yuan/share, and the minimum transaction price was 9.07 yuan/share. This repurchase complies with the requirements of the company's share repurchase plan and related laws and regulations .
Chenguang Biology (300138.SZ): Overseas marigold planting bases have a cost advantage over domestic production areas
Gelonghui, April 19 | Chenguang Biotech (300138.SZ) said on the investor interactive platform that the company's overseas marigold planting base has a cost advantage over domestic production areas. By expanding the area of overseas planting bases, it is possible to reduce the cost of the company's lutein products and enhance the market competitiveness of the products.
ChenGuang Biotech Group (SZSE:300138) Hasn't Managed To Accelerate Its Returns
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly, an expandi
Chenguang Biotech (300138.SZ): Net profit increased 10.53% year-on-year in 2023, and plans to distribute 1.3 yuan for 10 shares
Gelonghui, April 17 | Chenguang Biotech (300138.SZ) released its 2023 annual report. Operating revenue was 6.87 billion yuan, up 9.14% year on year, net profit of 480 million yuan, up 10.53% year on year, after deducting 367 million yuan in non-net profit, down 1.25% year on year, with basic earnings of 0.9017 yuan per share. A cash dividend of 1.3 yuan is distributed to all shareholders for every 10 shares.
Chenguang Biology (300138.SZ): Cottonseed products are similar to soybean products in downstream applications
Gelonghui, April 11 | Chenguang Biotech (300138.SZ) said on the investor interactive platform that the company's cottonseed products are similar to soybean products in downstream applications, and that cottonseed protein and cottonseed oil are correlated with the market prices of soybean meal and soybean oil.
Chenguang Biotech (300138.SZ): Net profit pre-reduced by 68.90%-75.56% in the first quarter
Gelonghui, April 9 | Chenguang Biotech (300138.SZ) announced its results forecast for the first quarter of 2024. Net profit profit attributable to shareholders of listed companies during the reporting period was 33 million yuan to 42 million yuan, down 75.56% to 68.90% from the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 43 million yuan to 52 million yuan, down 63.09% to 55.37% from the same period last year. Prices of cottonseed and other related products declined during the reporting period due to market fluctuations in commodities such as soybean oil and soybean meal. The results achieved in this type of business were high year-on-year
Chenguang Biotech (300138.SZ): 3.79% of shares have been repurchased
Gelonghui, April 2, 丨 Chenguang Biotech (300138.SZ) announced that as of March 31, 2024, the company had repurchased 20,172,808 shares through a dedicated securities account, with a transaction amount of RMB 243,656,694.24 (excluding transaction fees). The repurchased shares accounted for 3.79% of the company's total share capital. The highest transaction price of the shares repurchased was 14 yuan/share, and the lowest transaction price was 10.39 yuan/share.
ChenGuang Biotech Group Co., Ltd.'s (SZSE:300138) Market Cap up CN¥458m Last Week, Benefiting Both Individual Investors Who Own 55% as Well as Insiders
Key Insights ChenGuang Biotech Group's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 25 investors have a
Chenguang Biotech (300138.SZ): Accepted OEM production of NMN products commissioned by customers
Gelonghui, March 29丨Chenguang Biotech (300138.SZ) said on the investor interactive platform that the company had been commissioned by customers to manufacture NMN products, and the revenue from this business accounted for less than 0.1% of the overall business revenue for the year.
Chenguang Biotech (300138.SZ): Recently obtained 10 trademark registration certificates
Gelonghui March 21丨Chenguang Biotech (300138.SZ) announced that the company recently officially obtained ten trademark registration certificates issued by the State Intellectual Property Office.
Chenguang Biotech (300138.SZ): Currently exports goods to European countries normally
Gelonghui March 11 丨 Some investors asked Chenguang Biotech (300138.SZ) on the investor interactive platform, “Does the EU currently ban Chenguang products?” The company replied that it has not received information on the EU's ban on the sale of the company's products, and currently exports goods to European countries normally. According to the 2023 Annual Results Report, the company's annual exports generated more than US$180 million in foreign exchange.
Chenguang Biotech (300138.SZ) has repurchased a total of 18.778,200 shares at a cost of 228 million yuan
Zhitong Finance App News, Chenguang Biotech (300138.SZ) announced that as of February 29, 2024, the company had repurchased 187.782 million shares of the company through centralized bidding transactions, with a transaction amount of 228 million yuan (excluding transaction fees). The repurchased shares accounted for 3.52% of the company's total share capital.
Chenguang Biology (300138.SZ): The company's traditional Chinese medicine business is currently in the early stages of layout
Gelonghui, Feb. 27丨Chenguang Biotech (300138.SZ) said on the investor interactive platform that the company's traditional Chinese medicine business is currently in the early stages of layout. Hebei Chenguang Pharmaceutical Co., Ltd. specializes in the manufacture and sale of traditional Chinese medicine extracts, traditional Chinese medicine formula granules, etc., and Hebei Chenguang Tianrun Pharmaceutical Co., Ltd. specializes in the manufacture and sale of raw materials, pharmaceutical intermediates and other products.
Chenguang Biology (300138.SZ): The market share of the main products chili red, cayenne pepper extract, and lutein is at the top of the industry
Gelonghui February 20 丨 Chenguang Biology (300138.SZ) said on the investor interactive platform that the company's business is in the natural plant extract segment, and the market share of the main products red chili, chili extract, and lutein is at the top of the industry.
Chenguang Biotech (300138.SZ): A total of 3.09% shares have been repurchased
Gelonghui, February 7, 丨 Chenguang Biotech (300138.SZ) announced that as of February 6, 2024, the company had repurchased 16,485,658 shares of the company through a dedicated securities account, with a transaction amount of RMB 201,299,664.1 (excluding transaction fees). The repurchased shares accounted for 3.09% of the company's total share capital. The highest transaction price for the shares repurchased was 14 yuan/share, and the minimum transaction price was 10.39 yuan/share.
No Data